Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ATCOR MEDICAL HOLDINGS LIMITED
ABN	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	DONAL O'DWYER
Date of last notice	22 OCTOBER 2013

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	4,529,055 fully paid ordinary shares
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Dundrum Pty Ltd as trustee for The O'Dwyer Family Trust
Date of change	23 July 2015
No. of securities held prior to change	4,117,322 fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired	411,733
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$74,111.94
No. of securities held after change	4,529,055 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in rights offer

⁺ See chapter 19 for defined terms.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/a
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed	N/a
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade	
to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ATCOR MEDICAL HOLDINGS LIMITED
ABN	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	MICHAEL O'ROURKE
Date of last notice	22 OCTOBER 2013

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Indirect - 10,641,396 FPO shares
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Pehila Pty Ltd
Date of change	23 July 2015
No. of securities held prior to change	10,311,396 fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired	330,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$59,400.00
No. of securities held after change	10,641,396 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in rights offer

⁺ See chapter 19 for defined terms.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/a
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed	N/a
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade	
to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ATCOR MEDICAL HOLDINGS LIMITED
ABN	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	DAVID BROOKES
Date of last notice	22 OCTOBER 2013

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct 174 002 fully poid ordinary shares
Direct of indirect interest	Direct – 174,082 fully paid ordinary shares
	Indirect – 987,490 fully paid ordinary shares
Nature of indirect interest	DR D.L Brookes & Mrs E Brookes <dr d.l<="" td=""></dr>
(including registered holder)	Brookes Personal S/F A/c>
Note: Provide details of the circumstances giving rise to the relevant	2.001.001.01.001.01
interest.	
Date of change	23 July 2015
No. of socurities hold prior to change	009 257 fully paid ordinary charge
No. of securities held prior to change	908,257 fully paid ordinary shares
Class	Fully paid ordinary shares
Class	I dily paid ordinary strates
Number acquired	253,315
Number disposed	Nil
Number disposed	INII
Value/Consideration	\$45,596.70
Note: If consideration is non-cash, provide details and estimated	
valuation	
No. of securities held after change	1,161,572 fully paid ordinary shares
Nature of change	
Example: on-market trade, off-market trade, exercise of options,	Participation in rights offer including as sub-
issue of securities under dividend reinvestment plan, participation in	, ,
buy-back	underwriter.
	1

⁺ See chapter 19 for defined terms.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/a
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed	N/a
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade	
to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ATCOR MEDICAL HOLDINGS LIMITED
ABN	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	PETER JENKINS
Date of last notice	22 OCTOBER 2013

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct – 1,330,334 fully paid ordinary shares
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	23 July 2015
No. of securities held prior to change	1,209,394 fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired	120,940
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$21,769.20
No. of securities held after change	1,330,334 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in rights offer

⁺ See chapter 19 for defined terms.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/a
Nature of interest	
Name of registered holder	
(if issued securities)	
D. I. C. I.	
Date of change	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in relation to which the interest has changed	
relation to which the interest has changed	
Interest acquired	
Interest disposed	
·	
Value/Consideration	
Note: If consideration is non-cash, provide details	
and an estimated valuation	
Interest after change	
J	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed	N/a
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade	
to proceed during this period?	
If prior written clearance was provided, on what date was this	
provided?	

⁺ See chapter 19 for defined terms.